摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 2-amino-2-(naphthalen-1-yl)ethylcarbamate | 1044851-62-8

中文名称
——
中文别名
——
英文名称
tert-butyl 2-amino-2-(naphthalen-1-yl)ethylcarbamate
英文别名
1,1-dimethylethyl [2-amino-2-(1-naphthalenyl)ethyl]carbamate;1,1-dimethylethyl [2-amino-2-(naphthalen-1-yl)ethyl]carbamate;tert-butyl N-(2-amino-2-naphthalen-1-ylethyl)carbamate
tert-butyl 2-amino-2-(naphthalen-1-yl)ethylcarbamate化学式
CAS
1044851-62-8
化学式
C17H22N2O2
mdl
——
分子量
286.374
InChiKey
TVFGQBFXADIVOV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    64.4
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    申请人:Industrial Technology Research Institute
    公开号:US20190194137A1
    公开(公告)日:2019-06-27
    A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is —C(═Z)—, wherein Z is N—CN, NH, NR 4 , NCOR 4 , NCONR 4 R 5 , NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, —NH 2 , —CN, —OH, —O-alkyl, —O-aryl, —COOH, —COOR 4 , —CONHR 4 , —CONHCH 2 -aryl, —CONR 4 CH 2 -aryl, —NHCOR 4 , halogen, halogened alkyl, -alkyl-OR 4 , -alkyl-ONO 2 , alkyl-ONO 2 , —OCOOR 4 , —O(C═O)-aryl, —CHR 4 OH, —CH 2 OH, —CH 2 O(C═O)-aryl, —CH 2 O(C═O)—R 4 , —CHR 4 O(C═O)-aryl, —CHR 4 O(C═O)—R 4 , unsaturated carboxylic ester, substituted alkynyl, —NHSO 2 R 4 , —SO 2 R 4 , —SO 2 NHR 4 , or —SO 2 NR 4 R 5 , or Y and J bond together to form a carbocylic or aromatic ring, wherein R 4 and R 5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NR 6 R 7 , —S(O) 0-2 -(alkyl-NR 6 R 7 ). R 1 , R 2 and R 3 are H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO 2 , or NR 8 R 9 .
    提供公式(I)的化合物或其药用盐。在公式(I)中,Ar是吲唑,5-异喹啉,6-异喹啉或它们的N-氧化物。X为—C(═Z)—,其中Z为N—CN,NH,NR4,NCOR4,NCONR4R5,NCO-芳基,S或O。Y和J独立地为H,烷基,芳基,氨基烷基,—NH2,—CN,—OH,—O-烷基,—O-芳基,—COOH,—COOR4,—CONHR4,—CONHCH2-芳基,—CONR4CH2-芳基,—NHCOR4,卤素,卤代烷基,-烷基-OR4,-烷基-ONO2,烷基-ONO2,—OCOOR4,—O(C═O)-芳基,—CHR4OH,—CH2OH,—CH2O(C═O)-芳基,—CH2O(C═O)—R4,—CHR4O(C═O)-芳基,—CHR4O(C═O)—R4,不饱和羧酸酯,取代炔烃基,—NHSO2R4,—SO2R4,—SO2NHR4或—SO2NR4R5,或Y和J结合在一起形成环,其中R4和R5独立地为H,取代的C1-C6烷基,取代的芳基,环烷基,烷基芳基,-烷基-NR6R7,—S(O)0-2-(烷基-NR6R7)。R1,R2和R3为H,C1-C6烷基,环烷基,芳基,烷基芳基,烷基杂芳基,烷基杂环,其中任意一个可以选择地取代一个或多个OH,NO2或NR8R9。
  • Inhibitors of AKT Activity
    申请人:Novartis AG
    公开号:US20160287561A1
    公开(公告)日:2016-10-06
    Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    本发明涉及一种新型杂环羧酰胺化合物,其作为蛋白激酶B活性的抑制剂以及在癌症和关节炎治疗中的应用。
  • INHIBITORS OF Akt ACTIVITY
    申请人:Seefeld Mark A.
    公开号:US20100041726A1
    公开(公告)日:2010-02-18
    Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    本发明提供了一种新型杂环羧酰胺化合物,该化合物可用作蛋白激酶B活性的抑制剂,并可用于治疗癌症和关节炎。
  • INHIBITORS OF AKT ACTIVITY
    申请人:Seefeld Mark Andrew
    公开号:US20110053972A1
    公开(公告)日:2011-03-03
    Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    发明了新型杂环羧酰胺化合物,这些化合物可用作蛋白激酶B活性的抑制剂,并用于癌症和关节炎的治疗。
  • Inhibitors of Akt activity
    申请人:Seefeld Mark Andrew
    公开号:US08420690B2
    公开(公告)日:2013-04-16
    Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    发明了新型杂环羧酰胺化合物,这些化合物可用作蛋白激酶B活性的抑制剂,并用于癌症和关节炎的治疗。
查看更多